Zuclomiphene Limited Evidence

What It Is

Zuclomiphene is the cis (Z) stereoisomer of clomiphene citrate — a triphenylethylene small molecule of the same chemical family as tamoxifen and toremifene. Clomiphene citrate as commercially distributed (the FDA-approved fertility drug Clomid, approved 1967) is a roughly 38:62 mixture of zuclomiphene and enclomiphene; the two molecules share an identical molecular formula and connectivity but differ in the geometric orientation of the substituents around the central ethylene double bond.

That stereochemical difference produces dramatically divergent pharmacological behavior. Enclomiphene (the trans or E isomer) is an estrogen receptor antagonist that drives the testosterone-elevating, ovulation-inducing, anti-estrogenic activity for which clomiphene was originally developed. Zuclomiphene is its mirror twin in concept — a partial estrogen receptor agonist with predominantly estrogenic activity in many tissues, including the hypothalamus. The two isomers' coexistence in racemic clomiphene means a Clomid prescription delivers both pharmacologies simultaneously, with the cis fraction producing many of the clinical side effects (estrogenic effects, mood changes, visual disturbances, accumulation-related hot flashes) historically blamed on "clomiphene" as a single entity.

Zuclomiphene is also chemically lipophilic and slowly cleared. Its biological half-life is measured in weeks to months rather than days — and it accumulates in adipose tissue with chronic dosing. This pharmacokinetic property is the basis for clomiphene's months-long urinary detection window in anti-doping testing (Miller et al., JCEM 2019) and the foundation of the only contemporary clinical-development program for zuclomiphene as a standalone drug: long-acting, well-tolerated estrogen-receptor agonism delivered with the lipophilic depot pharmacokinetics of the cis-isomer.

Veru Inc., a Miami-based oncology and supportive-care company, isolated zuclomiphene citrate as VERU-944 (also designated APP-944) and conducted a Phase 2 dose-finding placebo-controlled trial (V72203) in men with advanced prostate cancer experiencing androgen-deprivation-therapy-induced moderate-to-severe hot flashes. Top-line results announced in January 2020 reported a statistically significant reduction in hot flash frequency. As of April 2026, the program has not advanced to FDA approval, and Veru's strategic focus has shifted to other compounds.

Mechanism of Action

Zuclomiphene's pharmacology is best understood by contrast with its trans isomer enclomiphene. Both molecules bind the estrogen receptor (ER); the cis configuration positions the diethylamino-ethoxy side chain such that the ER ligand-binding domain adopts a conformation favoring agonist activity at most ER-expressing tissues, while the trans configuration positions the same side chain to favor antagonist activity. The result is two molecules with opposing functional profiles arising from a single bond rotation.

• Estrogen receptor agonism (predominant) — Zuclomiphene functions as a partial agonist at ERα and ERβ in most tissue contexts. In the hypothalamus, this agonist activity provides exogenous estrogenic tone that suppresses the kisspeptin / neurokinin B / dynorphin (KNDy) neurons in the arcuate nucleus that become hyperactive when endogenous estrogen drops (in menopausal women, in men on androgen deprivation therapy, and in androgen-replete men whose estradiol is suppressed by aromatase inhibition). By reducing KNDy hyperactivity, zuclomiphene reduces NKB-mediated stimulation of the NK3R-expressing neurons in the median preoptic nucleus that trigger vasomotor symptoms — the mechanistic rationale for the Veru hot-flash program.
• Antigonadotropic effect in men — In contrast to enclomiphene, which raises LH/FSH and downstream testosterone by blocking hypothalamic estrogen-mediated negative feedback, zuclomiphene's hypothalamic agonist activity produces the opposite functional effect — it provides exogenous estrogenic feedback to the hypothalamus, suppressing rather than stimulating gonadotropin secretion. With chronic accumulation, zuclomiphene attenuates and can reverse the testosterone-restoring effect of co-administered enclomiphene (the central pharmacological argument for separating the isomers in male hypogonadism therapy).
• Long lipophilic half-life (weeks to months) — The lipophilic triphenylethylene scaffold combined with the cis configuration drives extensive partitioning into adipose tissue and very slow elimination. After a single 50 mg dose of racemic clomiphene, zuclomiphene remains detectable in plasma for weeks; in chronic dosing, steady-state accumulation continues for months before plateau. This pharmacokinetic profile is the practical reason racemic clomiphene gradually loses efficacy in men over multi-month courses.
• Differential tissue effects (SERM behavior) — Like all selective estrogen receptor modulators, zuclomiphene exhibits tissue-specific agonist / antagonist profiles depending on local ER coregulator availability. Bone effects in published animal models suggest agonist-like (bone-preserving) activity, with potential utility in androgen-deprivation osteopenia. Endometrial agonist activity creates theoretical concern in women, mirroring tamoxifen's endometrial considerations, although standalone female zuclomiphene exposure is minimal.
• Anti-Ebola and antiviral activity (preclinical) — Both isomers have been shown to inhibit Ebola virus infection in cell culture by interfering with viral entry through endolysosomal membrane interactions, an activity attributed to the cationic amphiphilic small-molecule structure rather than the SERM pharmacology. This is a preclinical observation without clinical translation.
• CYP2D6 metabolism — Both clomiphene isomers are metabolized in the liver, with CYP2D6 contributing to enclomiphene clearance and apparently less to zuclomiphene clearance (based on the JCEM 2019 metabolic divergence observation). Patients with CYP2D6 polymorphisms may have altered enclomiphene pharmacokinetics without proportional alterations to zuclomiphene.

What the Research Shows

Standalone zuclomiphene research is sparse — until the Veru clinical program, the molecule was studied almost exclusively as a component of racemic clomiphene rather than as a discrete pharmaceutical candidate. The published evidence base falls into three buckets:

• Pharmacokinetic / pharmacodynamic isolation studies — Mikkelson et al. (1986; American Fertility Society) and the 2009 single-dose PK study (PMID 19033451) characterized the dramatically divergent half-lives of the two clomiphene isomers in PCOS patients receiving 50 mg racemic clomiphene. Plasma zuclomiphene concentrations remained detectable through day 21 of follow-up in nearly all subjects; enclomiphene cleared within days. The "long terminal half-life and long-tailed residence time" reported is the pharmacokinetic signature of the lipophilic cis-isomer.
• Anti-doping detection window — The 2019 JCEM controlled study by Miller et al. (PMID 30649263) administered clomiphene citrate to healthy male volunteers and characterized urinary detection windows for both isomers, plus serum testosterone and gonadotropin responses. Zuclomiphene-positive urine samples extended for several months post-administration in some subjects, while enclomiphene cleared more rapidly. This established the WADA-relevant detection window for clomiphene-class compounds and confirmed that long-tail zuclomiphene is the analytical signature of a prior clomiphene exposure.
• Mouse ADME study (Hill et al.) — A radiolabeled mouse ADME study using ¹⁴C-zuclomiphene and ¹⁴C-enclomiphene confirmed dissimilar tissue distributions and elimination kinetics for the two isomers, with zuclomiphene showing prolonged plasma residence and broader tissue distribution.
• VERU-944 Phase 2 (V72203) — Veru Inc's pivotal standalone zuclomiphene trial. A double-blind, randomized, placebo-controlled, dose-finding study evaluating 10 mg vs 50 mg daily oral zuclomiphene capsules over 12 weeks in 24 U.S. clinical centers, in men with advanced prostate cancer experiencing ADT-induced moderate-to-severe hot flashes. Top-line interim results announced January 2020 reported statistically significant reduction in moderate-to-severe hot flash frequency versus placebo. ASCO trial abstract: Getzenberg RH et al., J Clin Oncol 2019;37(7_suppl):TPS338.
• Position in ADT hot-flash management — The 2025 Joshua review in J Clin Endocrinol Metab (PMID 40397707) — "A Review of Hot Flash Management in Patients With Prostate Cancer" — situates zuclomiphene as one of several emerging therapies alongside neurokinin-3 receptor antagonists (fezolinetant, elinzanetant) for ADT-induced vasomotor symptoms. Standard of care remains oxybutynin, antidepressants (venlafaxine, paroxetine), and behavioral measures; zuclomiphene and NK3R antagonists are positioned as candidate next-line therapies pending Phase 3 confirmation.
• Comparator: enclomiphene male hypogonadism — The mechanistic rationale for separating the isomers in male SERM therapy is supported by Wiehle 2014 (PMID 24833744 — enclomiphene vs racemic clomiphene), Kaminetsky 2013 (PMID 23411589 — enclomiphene Phase 2), and Saffati 2024 (PMID 39434750 — enclomiphene vs clomiphene safety/efficacy). These are not zuclomiphene trials but they document that removing the zuclomiphene fraction from clomiphene reduces estrogenic side effects and produces more sustained testosterone elevation in men.

Human Data

Human zuclomiphene data falls into two narrow categories: pharmacokinetic studies of clomiphene's component isomers, and the Veru Phase 2 hot-flash program.

• Mikkelson 1986 (Fertil Steril) — Pharmacokinetics of three formulations of clomiphene citrate in healthy volunteers; characterized plasma zuclomiphene and enclomiphene concentrations and metabolites. Established the dramatically longer terminal half-life of zuclomiphene relative to enclomiphene.
• Mahesh / Ghosh 2009 (PMID 19033451) — Single-dose 50 mg clomiphene PK in 9 PCOS patients. Plasma zuclomiphene and enclomiphene measured day 1 through day 21. Conventional model-dependent PK could not be determined due to flat terminal half-life and long-tailed residence time of zuclomiphene — demonstrating its lipophilic distribution.
• Miller 2019 JCEM (PMID 30649263) — Controlled clomiphene administration in healthy adult male volunteers; primary endpoint was hypothalamic-pituitary-testicular axis effects and urinary detection of clomiphene isomers. Zuclomiphene detectable in urine for months post-administration. Documented isomer-specific accumulation pattern in men.
• VERU-944 Phase 2 V72203 (Getzenberg 2019; positive interim 2020) — Double-blind, randomized, placebo-controlled, dose-finding 12-week trial in men with advanced prostate cancer on ADT with moderate-to-severe hot flashes. Doses: 10 mg vs 50 mg vs placebo daily. Top-line interim data reported statistically significant reduction in moderate-to-severe hot flash frequency on zuclomiphene vs placebo.
• Inferred safety from clomiphene experience — Because zuclomiphene comprises 30–50% of racemic clomiphene, and clomiphene has a 50+ year clinical safety record at doses up to ~400 mg/day in men, zuclomiphene's general tolerability at doses of 10–50 mg/day can be inferred to be acceptable. This is indirect evidence, not standalone safety data.
• No Phase 3 readout — As of April 2026, no Phase 3 trial of zuclomiphene has been completed. Veru indicated Phase 3 plans following the 2020 Phase 2 data but the program has not produced a publicly disclosed Phase 3 readout, and Veru's pipeline focus has shifted to other compounds (sabizabulin, enobosarm).

Dosing from the Literature

Standalone zuclomiphene dosing is anchored to the Veru Phase 2 program. Doses in the racemic clomiphene literature are not directly comparable because the racemic mix delivers zuclomiphene as a 30–50% fraction of total dose alongside enclomiphene.

Reconstitution & Storage

Zuclomiphene is a small molecule administered orally as a capsule. There is no reconstitution requirement for the Veru clinical formulation (oral solid). Research-grade powder for laboratory use is supplied by analytical and reference-standard vendors:

• Solubility — Free base sparingly soluble in water; soluble in ethanol, DMSO, methanol. Citrate salt has improved aqueous solubility; pharmaceutical formulation is the citrate.
• Photostability — Triphenylethylene scaffold is light-sensitive (can undergo cis/trans photoisomerization on UV exposure). Store powder and solutions protected from light.
• Long-term stability — Lyophilized / crystalline powder stable for years at −20°C. Reconstituted DMSO solutions stable for months at −80°C.

Side Effects & Risks

Zuclomiphene's standalone safety profile is inferred largely from clomiphene experience plus the limited Phase 2 data:

• Estrogenic side effects — As an estrogen receptor agonist, zuclomiphene's predictable side-effect profile mirrors mild estrogen excess: gynecomastia in men, breast tenderness, water retention, mood lability. The Veru Phase 2 trial reported acceptable tolerability at 10–50 mg/day; full safety profile across the program has not been published in detail.
• Visual disturbances — Triphenylethylene SERMs (clomiphene, tamoxifen) carry a documented risk of visual symptoms including blurred vision, scotomata, and reversible retinal effects. The mechanism involves binding to retinal estrogen receptors and possible photochemical effects of the triphenylethylene chromophore. Reports are infrequent but well documented in the racemic clomiphene literature; standalone zuclomiphene incidence has not been characterized separately.
• Mood effects — Mood changes including depression and irritability are reported with clomiphene use. The cis-isomer fraction is suspected to contribute given its central agonist activity at hypothalamic and limbic ER sites.
• Thromboembolic risk — All SERMs carry a class-level risk of venous thromboembolism by mechanisms shared with estrogenic agents. Clinical incidence with low-dose zuclomiphene appears low but the class concern applies.
• Endometrial effects (women) — Long-term agonist exposure at the endometrium is theoretically concerning by analogy with tamoxifen. Zuclomiphene has not been studied in women as a standalone chronic exposure; the Veru program is in men.
• Bone effects — Possibly bone-protective via ER agonist activity; data limited.
• Infertility / antigonadotropic effect (men) — Chronic zuclomiphene exposure in men suppresses gonadotropin release and lowers testosterone — the opposite of enclomiphene's effect. This is a feature for the hot-flash indication (the goal in ADT patients is not to restore testosterone) but a clear contraindication for any application in eugonadal men seeking to maintain fertility or testosterone.
• Drug interactions — CYP2D6 substrate; potential interactions with strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion) and inducers. Concurrent administration with tamoxifen or other SERMs is not characterized.
• Long accumulation half-life — The most distinctive safety concern. Months-long elimination means dose adjustments take months to manifest; intentional discontinuation does not produce rapid washout. Cumulative chronic dosing risks are theoretically front-loaded by accumulation rather than acute single-dose effects.
• Pregnancy and lactation — Clomiphene is contraindicated in pregnancy (Pregnancy Category X); standalone zuclomiphene shares this contraindication by analogy. Long elimination half-life means a clinically significant washout period (months) is required before conception attempts in women, although standalone female zuclomiphene exposure is currently negligible.

Bloodwork & Monitoring

No established monitoring protocol exists for standalone zuclomiphene outside the Veru clinical program. For research-context awareness:

• Baseline CMP, CBC, lipid panel — Standard pre-treatment chemistry.
• Hormonal panel (men) — Total and free testosterone, estradiol (sensitive assay), LH, FSH, SHBG. Expect testosterone suppression and gonadotropin suppression with chronic zuclomiphene; this is the predicted effect, not a side effect.
• Visual symptom screening — Document baseline visual function; advise prompt ophthalmologic evaluation for any new visual disturbance.
• Mood assessment — Baseline and serial assessment, particularly given the central ER agonist activity and the documented mood effects of clomiphene-class SERMs.
• VTE risk assessment — Class-level SERM concern; document personal and family history of thromboembolism, evaluate concurrent estrogen exposures.
• Hot flash diary (Veru-trial format) — In the hot-flash indication, frequency and severity of moderate-to-severe vasomotor symptoms is the primary outcome measure.

Commonly Stacked With

Zuclomiphene is not a community-use compound. There is no established stacking literature. Conceptual contexts in which zuclomiphene might be relevant:

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching Zuclomiphene often also look at these:

Next Steps

Key References

1. Ghosh BR, Speroff L, Ke RW, Nelson DM, Soules MR. Single-dose pharmacokinetic study of clomiphene citrate isomers in anovular patients with polycystic ovary disease. J Clin Pharmacol. 2009;49(6):674-684. PMID: 19033451.
2. Mikkelson TJ, Kroboth PD, Cameron WJ, Dittert LW, Chungi V, Manberg PJ. Single-dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertil Steril. 1986;46(3):392-396.
3. Miller GD, Moore C, Nair V, Hill B, Willick SE, Rogol AD, Eichner D. Hypothalamic-Pituitary-Testicular Axis Effects and Urinary Detection Following Clomiphene Administration in Males. J Clin Endocrinol Metab. 2019;104(3):906-914. PMID: 30649263. (The controlled male PK/detection-window study; characterizes zuclomiphene's months-long urinary persistence — the WADA-relevant signal.)
4. Getzenberg RH, Rodriguez D, Hancock ML, Fisch H, Steiner MS. A phase II, dose finding, placebo-controlled, study of zuclomiphene citrate to ameliorate the frequency and severity of hot flashes caused by androgen deprivation in men with advanced prostate cancer. J Clin Oncol. 2019;37(7_suppl):TPS338. (Veru V72203 / VERU-944 trial design abstract.)
5. Veru Inc. Press release: "Veru Announces Positive Top-Line Interim Data from Phase 2 Clinical Trial of Zuclomiphene to Treat Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy." January 13, 2020. (Top-line interim Phase 2 efficacy disclosure for VERU-944.)
6. Joshua AM. A Review of Hot Flash Management in Patients With Prostate Cancer. J Clin Endocrinol Metab. 2025;110(9):2509-2519. PMID: 40397707. (Contemporary review of vasomotor-symptom management in ADT, including zuclomiphene and NK3R antagonists.)
7. Cilento MA, Butler LM, Sweeney CJ. Personalized intensification of treatment for hormone-sensitive prostate cancer. Nat Rev Clin Oncol. 2026;23(2):121-136. (Contemporary ADT context including supportive care.)
8. Mehring AL, Chamoun P, Stephenson C, et al. Management of vasomotor symptoms in cancer patients. PMC11879400. (KNDy / NK3R mechanism review situating zuclomiphene's site of action.)
9. Wiehle RD, Fontenot GK, Wike J, Hsu K, Nydell J, Lipshultz L; ZA-203 Clinical Study Group. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014;102(3):720-727. PMID: 24833744. (The mechanistic counter-case for separating the isomers.)
10. Kaminetsky J, Werner M, Fontenot G, Wiehle RD. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. J Sex Med. 2013;10(6):1628-1635. PMID: 23411589.
11. Saffati G, Kassab J, Orozco Rendon D, Hinojosa-Gonzalez DE, Kronstedt S, Lipshultz LI, Khera M. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men. Transl Androl Urol. 2024;13(9):1984-1990. PMID: 39434750.
12. Hill SE, Bell M, Fontenot G, Wiehle RD. The Isomers of Clomiphene Citrate have Dissimilar Dispositions Once Ingested: Results of a Mouse ADME Study. (Mouse radiolabeled distribution and elimination study confirming divergent isomer pharmacokinetics.)
13. StatPearls. Clomiphene. NCBI Bookshelf NBK559292. (Reference drug monograph; confirms zuclomiphene's months-long terminal half-life in healthy volunteers.)
14. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID: 29562364. (Context: standard-of-care for low testosterone — the field zuclomiphene's hypothetical SERM role does not displace.)
15. WADA. The 2026 Prohibited List. World Anti-Doping Agency. wada-ama.org. (Class S4: Hormone and Metabolic Modulators, including SERMs and clomiphene class.)
16. U.S. FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book): Clomiphene Citrate. fda.gov. (Documents the approved racemic clomiphene formulation; standalone zuclomiphene is not approved.)
17. Adashi EY. Clomiphene citrate-initiated ovulation: a clinical update. Semin Reprod Endocrinol. 1996;14(3):255-263. (Historical pharmacology review of racemic clomiphene establishing isomer composition.)
18. Quaas AM, Legro RS. Pharmacology of medications used for ovarian stimulation. Best Pract Res Clin Endocrinol Metab. 2019;33(1):21-33. (Clinical pharmacology context for clomiphene isomers.)
19. WADA Prohibited List Documentation. Class S4 Hormone and Metabolic Modulators. World Anti-Doping Agency. (Documents clomiphene class status under SERM banned-substance category.)
20. Veru Inc Form 10-K. Securities and Exchange Commission filings 2020–2024. (Public-disclosure pipeline updates regarding the VERU-944 / APP-944 zuclomiphene program status.)